Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19) - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Clinical and Translational Immunology Année : 2020

Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)

Résumé

Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease-19 (COVID-19). Although placebo-controlled, double-blind randomised clinical trials are lacking, current data from either retrospective, case series or open-label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID-19 patients. See alsoShao et al.

Dates et versions

hal-03905108 , version 1 (17-12-2022)

Identifiants

Citer

Caroline Galeotti, Srini Kaveri, Jagadeesh Bayry. Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19). Clinical and Translational Immunology, 2020, 9 (10), pp.e1198. ⟨10.1002/cti2.1198⟩. ⟨hal-03905108⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More